U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07098806) titled 'Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases' on July 02.
Brief Summary: This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.
Study Start Date: July 02
Study Type: INTERVENTIONAL
Condition:
Leptomeningeal Metastasis
Intervention:
DRUG: 186RNL
Mult...